Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02170870 · ClinicalTrials.gov registry record · Phase 2
Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT02170870: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT02170870 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02170870, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to understand why people with indigestion have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine and to a hormone (GLP1) which is normally released from the small intestine in response to nutrients. We propose to study the contribution of GLP1 to intestinal sensitivity with a drug (exendin 9-39) that blocks the effects of GLP1.
Interventions
- DRUG Placebo
- DRUG Exendin 9-39
- DRUG Microlipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02170870
The ClinicalTrials.gov registry entry for NCT02170870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02170870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02170870 about?
NCT02170870 is a clinical study titled "Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus". The purpose of this study is to understand why people with indigestion have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine and to a hormone (GLP1) which is normally released from the small intestine ...
What is the current status of trial NCT02170870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2014-06. Estimated completion is 2017-11-17.
What interventions are being tested in trial NCT02170870?
The interventions under investigation include: Placebo (DRUG), Exendin 9-39 (DRUG), Microlipid (DRUG).
Who is sponsoring clinical trial NCT02170870?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.